Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5928837 | American Heart Journal | 2013 | 12 Pages |
Abstract
Recent advances in electrocardiographic monitoring and waveform analysis have significantly improved the ability to detect drug-induced changes in cardiac repolarization manifested as changes in the QT/corrected QT interval. These advances have also improved the ability to detect drug-induced changes in cardiac conduction. This White Paper summarizes current opinion, reached by consensus among experts at the Cardiac Safety Research Consortium, on the assessment of electrocardiogram-based safety measurements of the PR and QRS intervals, representing atrioventricular and ventricular conduction, respectively, during drug development.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Adel MD, MS, MFPM, Gary A. PhD, Robert MD, David E. MD, Christer MD, PhD, Eric L. MD, Colette PhD, Matthew MD, Mary Jane MD, PhD, Mónica L. MD, PhD, Luana Pesco MD, Glenn F. MD, Ignacio MD, Philip T. MD,